# ğŸ“Š Dummy Data Expansion Summary

**Date:** 2026-02-10  
**Purpose:** Enhanced demo data for Treatment Timeline and analytics testing  
**Status:** COMPLETE

---

## âœ… What Was Added

### **12 New Patient Records (TL-001 through TL-012)**

**Total Patient Count:**
- **Before:** 4 patients (EX-001 through EX-004)
- **After:** 16 patients (4 original + 12 new)
- **Increase:** 300% more demo data

---

## ğŸ“‹ New Patient Record Types

### **1. Multi-Session Treatment Timelines (TL-001, TL-002, TL-003, TL-004)**
**Purpose:** Demonstrate temporal progression over multiple sessions

- **TL-001:** 4 sessions over 16 days (Psilocybin 25mg)
  - PHQ-9: 18 â†’ 15 â†’ 12 â†’ 11 (39% improvement)
  - Demonstrates steady improvement

- **TL-002:** 5 sessions over 28 days (Psilocybin 50mg)
  - PHQ-9: 21 â†’ 17 â†’ 14 â†’ 9 â†’ 6 (71% improvement)
  - Includes 1 adverse event (Nausea, Grade 2)
  - Demonstrates strong response with SSRI co-administration

- **TL-003:** 4 sessions over 3 months (MDMA 100mg)
  - PHQ-9: 19 â†’ 14 â†’ 8 â†’ 4 (79% improvement, remission)
  - Demonstrates monthly dosing schedule

- **TL-004:** 5 sessions over 28 days (Ketamine IV)
  - MADRS: 28 â†’ 22 â†’ 18 â†’ 14 â†’ 12 (57% improvement)
  - Demonstrates weekly IV ketamine protocol

---

### **2. Substance Switch Example (TL-005)**
**Purpose:** Show treatment adaptation when initial substance underperforms

- **Sessions 1-2:** Psilocybin (25mg, 50mg)
  - PHQ-9: 20 â†’ 16 (20% improvement)
- **Sessions 3-4:** MDMA (100mg, 120mg)
  - PHQ-9: 13 â†’ 8 (60% total improvement)
- **Key Insight:** Substance switch led to accelerated improvement

---

### **3. Dose Escalation Example (TL-006)**
**Purpose:** Demonstrate titration protocol

- **Session 1:** 15mg Psilocybin â†’ PHQ-9: 22
- **Session 2:** 25mg Psilocybin â†’ PHQ-9: 19
- **Session 3:** 35mg Psilocybin â†’ PHQ-9: 15
- **Session 4-5:** 50mg Psilocybin â†’ PHQ-9: 11 â†’ 7
- **Total Improvement:** 68%

---

### **4. High-Frequency Treatment (TL-007)**
**Purpose:** Show twice-weekly ketamine protocol

- **7 sessions over 21 days** (Ketamine IV, 0.5mg/kg)
- PHQ-9: 26 â†’ 23 â†’ 19 â†’ 16 â†’ 13 â†’ 10 â†’ 8 (69% improvement)
- **Demonstrates:** Rapid treatment schedule effectiveness

---

### **5. Rapid Responder (TL-008)**
**Purpose:** Show exceptional treatment response

- **3 sessions over 14 days** (Psilocybin 30mg)
- PHQ-9: 24 â†’ 9 â†’ 4 (83% improvement, remission)
- **Key Insight:** >30% improvement in first 2 sessions

---

### **6. Non-Responder with Adverse Events (TL-009)**
**Purpose:** Show treatment challenges and safety monitoring

- **3 sessions over 2 months** (LSD-25 150ug)
- GAD-7: 17 â†’ 18 â†’ 16 (no improvement, slight worsening)
- **Adverse Events:**
  - Session 1: Severe anxiety (Grade 3), required benzodiazepine
  - Session 2: Panic attack (Grade 2)
- **Status:** Observation (treatment may be discontinued)

---

### **7. Long-Term Maintenance (TL-010)**
**Purpose:** Show quarterly maintenance dosing

- **4 sessions over 9 months** (Psilocybin 25mg)
- PHQ-9: 20 â†’ 8 â†’ 5 â†’ 4 (80% improvement, sustained remission)
- **Demonstrates:** Long-term efficacy with infrequent dosing

---

### **8. Route Change Example (TL-011)**
**Purpose:** Show route of administration adaptation

- **Sessions 1-2:** Ketamine IV â†’ PHQ-9: 25 â†’ 21
- **Sessions 3-5:** Ketamine IM â†’ PHQ-9: 17 â†’ 13 â†’ 9
- **Total Improvement:** 64%
- **Key Insight:** Route change maintained efficacy

---

### **9. Combination Therapy (TL-012)**
**Purpose:** Show multi-modality integration

- **4 sessions over 42 days** (MDMA 125mg)
- PHQ-9: 23 â†’ 18 â†’ 12 â†’ 7 (70% improvement)
- **Modalities:** IFS + Somatic + Psychodynamic
- **Adverse Event:** Tachycardia (Grade 2, monitored)

---

## ğŸ“Š Data Coverage Summary

### **Substances Represented:**
- âœ… Psilocybin (8 patients)
- âœ… MDMA (4 patients)
- âœ… Ketamine (4 patients)
- âœ… LSD-25 (2 patients)

### **Routes of Administration:**
- âœ… Oral (12 patients)
- âœ… Intravenous (3 patients)
- âœ… Intramuscular (1 patient)

### **Treatment Frequencies:**
- âœ… Single session (1 patient)
- âœ… Weekly (3 patients)
- âœ… Twice weekly (2 patients)
- âœ… Bi-weekly (3 patients)
- âœ… Monthly (3 patients)
- âœ… Quarterly (1 patient)

### **Outcome Ranges:**
- âœ… Remission achieved (3 patients)
- âœ… Strong improvement (6 patients)
- âœ… Moderate improvement (4 patients)
- âœ… No improvement/worsening (1 patient)

### **Safety Events:**
- âœ… No adverse events (9 patients)
- âœ… Grade 2 events (3 patients)
- âœ… Grade 3 events (1 patient)

### **Concomitant Medications:**
- âœ… No meds (5 patients)
- âœ… SSRIs (3 patients)
- âœ… SNRIs (2 patients)
- âœ… Benzodiazepines (1 patient)
- âœ… Antipsychotics (1 patient)
- âœ… Other (4 patients)

---

## ğŸ¯ Use Cases Enabled

### **1. Treatment Timeline Visualization**
- âœ… Multiple sessions per patient (3-7 sessions)
- âœ… Day-level temporal precision
- âœ… Outcome progression tracking
- âœ… Substance switches
- âœ… Dose escalations

### **2. Filtering & Analysis**
- âœ… Filter by substance
- âœ… Filter by outcome range
- âœ… Filter by adverse events
- âœ… Filter by concomitant meds
- âœ… Filter by treatment frequency

### **3. Pattern Detection**
- âœ… Rapid responders (TL-008)
- âœ… Non-responders (TL-009)
- âœ… Dose-response relationships (TL-006)
- âœ… Treatment frequency impact (TL-007)

### **4. Safety Analysis**
- âœ… Adverse event frequency
- âœ… Severity grade distribution
- âœ… Drug interaction examples

### **5. Cohort Comparisons**
- âœ… Substance efficacy (Psilocybin vs MDMA vs Ketamine)
- âœ… Route comparison (IV vs IM vs Oral)
- âœ… Frequency comparison (Weekly vs Monthly)

---

## ğŸ” Data Quality

### **Realistic Patterns:**
- âœ… PHQ-9 scores follow clinically plausible trajectories
- âœ… Improvement rates vary (0-83%)
- âœ… Adverse events occur at realistic frequencies (~25%)
- âœ… Concomitant medications reflect real-world polypharmacy

### **Temporal Realism:**
- âœ… Day intervals match treatment protocols
- âœ… Session dates are sequential
- âœ… Treatment frequencies are clinically appropriate

### **Diversity:**
- âœ… Age range: 26-52 years
- âœ… Gender: 7 female, 9 male
- âœ… Weight range: 58-92 kg
- âœ… Multiple sites (NODE-01, NODE-02, NODE-04, NODE-07)

---

## ğŸ“ Files Modified

**`src/constants.ts`**
- Added 12 new patient records (TL-001 through TL-012)
- Expanded PATIENTS array from 4 to 16 records
- Added 479 lines of new demo data

---

## âœ… Testing Checklist

Use these patients to test:

- [ ] **Timeline Chart:** TL-001 (4 sessions, steady improvement)
- [ ] **Substance Switch:** TL-005 (Psilocybin â†’ MDMA)
- [ ] **Dose Escalation:** TL-006 (15mg â†’ 50mg)
- [ ] **High Frequency:** TL-007 (7 sessions in 21 days)
- [ ] **Rapid Responder:** TL-008 (83% improvement)
- [ ] **Non-Responder:** TL-009 (no improvement + AEs)
- [ ] **Long-Term:** TL-010 (9 months, quarterly)
- [ ] **Route Change:** TL-011 (IV â†’ IM)
- [ ] **Adverse Events:** TL-002, TL-009, TL-012
- [ ] **Filtering:** All 16 patients

---

## ğŸš€ Next Steps

1. **INVESTIGATOR:** Validate data structure matches database schema
2. **BUILDER:** Use TL-001 for initial timeline implementation
3. **BUILDER:** Test filtering with full 16-patient dataset
4. **DESIGNER:** Review timeline visualization with diverse data
5. **USER:** Test demo with realistic patient scenarios

---

**Data Expansion Complete** âœ…

**Ready for:**
- Treatment Timeline implementation
- Filtering and analysis features
- Demo presentations
- User testing

---

**End of Summary**
